In the ongoing study AIEOP-BFM ALL 2017, the VHR subgroup with an indication for HSCT in non-infants is defined by (1) the presence of TCF3-HLF gene fusion, (2) KMT2A-AFF1 gene fusion, (3) hypodiploidy, (4) IKZF1plus deletions with FCM-MRD d15 HR and SER, (5) PCR-MRD HR, and (6) T-ALL with PPR and/or FCM-MRD d15 HR and/or IF. This evidence concerns the gene AFF1 and acute lymphoblastic leukemia.